David Moatazedi Sells 16,582 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 16,582 shares of Evolus stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.89, for a total transaction of $163,995.98. Following the completion of the sale, the insider now owns 364,927 shares of the company’s stock, valued at $3,609,128.03. This represents a 4.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

David Moatazedi also recently made the following trade(s):

• On Friday, June 13th, David Moatazedi sold 111,323 shares of Evolus stock. The stock was sold at an average price of $10.05, for a total transaction of $1,118,796.15.
• On Monday, May 12th, David Moatazedi sold 15,787 shares of Evolus stock. The shares were sold at an average price of $9.87, for a total transaction of $155,817.69.
• On Thursday, March 27th, David Moatazedi sold 6,251 shares of Evolus stock. The shares were sold at an average price of $12.40, for a total value of $77,512.40.

Evolus Stock Performance

Shares of NASDAQ:EOLS traded up $0.03 during midday trading on Monday, hitting $9.96. The company had a trading volume of 762,050 shares, compared to its average volume of 742,318. Evolus, Inc. has a 12-month low of $8.67 and a 12-month high of $17.82. The company has a fifty day moving average of $10.31 and a two-hundred day moving average of $11.77. The company has a market cap of $642.18 million, a price-to-earnings ratio of -10.94 and a beta of 1.00. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Wall Street Analyst Weigh In

A number of research firms recently commented on EOLS. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Thursday, May 8th. Barclays boosted their price target on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday, April 10th. Finally, BTIG Research initiated coverage on shares of Evolus in a report on Thursday, April 17th. They issued a “buy” rating and a $21.00 price objective on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $23.75.

Institutional Trading of Evolus

Hedge funds have recently bought and sold shares of the stock. AlphaQuest LLC purchased a new position in shares of Evolus during the 1st quarter valued at about $39,000. State of Wyoming raised its stake in Evolus by 988.1% during the 1st quarter. State of Wyoming now owns 3,754 shares of the company’s stock worth $45,000 after acquiring an additional 3,409 shares during the period. IFP Advisors Inc lifted its holdings in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after purchasing an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Evolus during the fourth quarter valued at approximately $106,000. Finally, Rafferty Asset Management LLC bought a new position in shares of Evolus in the fourth quarter worth approximately $115,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.